COVID-19 IgG-related autoimmune inflammatory necrotizing myositis

Maede Veyseh,1,2 Sai Koyoda,2 Bibi Ayesha

SUMMARY
The COVID-19 pandemic caused by the SARS-CoV-2 virus has affected millions of people around the globe. The most common presentation of COVID-19 is fever and upper and lower respiratory tract infection. Myalgia is fairly common in the prodromal phase of the viral illness which self-resolves. There is very scant literature on autoimmune myositis triggered by COVID-19 infection. We report a case of SARS-CoV-2 infection, who presented with progressive muscle weakness with rhabdomyolysis and necrotizing autoimmune myopathy on muscle biopsy. This case report imposes awareness of musculoskeletal autoimmune processes triggered by COVID-19 which requires clinical suspicion for early diagnosis and initiation of treatment.

BACKGROUND
Since the emergence of the global pandemic of COVID-19, clinicians have been learning and exploring this new disease entity and managing the repercussions of the current health crisis. COVID-19 manifests with a wide range of presentations, most commonly with fever and upper and lower respiratory tract infection.1,2 The musculoskeletal manifestations include myalgia and fatigue, which are common in any prodromal phase of viral disease.3 The myositis associated with COVID-19 described as skeletal muscle injury and rhabdomyolysis have also been reported in up to 10% of infected patients.4 The COVID-19 disease process triggers an autoimmune inflammatory response which has been reported in the literature as few case reports.5–7 There is very scant literature on autoimmune myositis triggered by COVID-19 infection. We report a case of necrotizing autoimmune myopathy (NAM) associated with COVID-19. NAM is an unusual and rare subgroup of inflammatory myopathies which is confirmed by necrotic muscle fibres and absent or minimal inflammation on muscle biopsy. The etiology is usually idiopathic; however, it has also been associated with statin use, triggered by post-viral autoimmune antibodies, and sometimes has manifested as paraneoplastic presentation.8 The exact mechanism of muscle injury is not well understood, but the exaggerated inflammatory response and the viral infection of the skeletal cells are the suggested pathophysiology of myositis in these patients.9 It is important as a clinician to recognize the typical and atypical presentations of COVID-19 for timely intervention and to improve patient outcomes.

CASE PRESENTATION
This is a case of a 57-year-old woman with medical history of hypertension, who had COVID-19-related mild upper respiratory infection, for which she self-quarantined at home and recovered gradually after 2 weeks. A month after the initial COVID-19 disease, she started to experience worsening dyspnoea and presented to the hospital. Initial examination and vital signs were reported within normal limits. She was noted to have positive SARS-CoV-2 immunoglobulin G (IgG) antibody and negative SARS-CoV-2 PCR, elevated creatine kinase (15,000 IU/L) and elevated troponin (1.4 μg/L) with normal kidney function. The ECG, echocardiogram and cardiac MRI were normal. The most likely diagnosis at the time of discharge was found to be rhabdomyolysis in the setting of COVID-19 disease. The patient was managed symptomatically and discharged home once stabilised.

Four months after the initial COVID-19 infection, she presented to the hospital again with worsening muscle weakness for 2 weeks. She was unable to get up from a seated position or lift arms above her head. On physical examination, the patient had vital signs reported within a normal range. On physical examination, she had 3/5 power in the right foot and 5/5 in the left foot and 5/5 in all other muscle groups. She had bilateral foot drop. On 21 May 2020, she presented to the hospital again with worsening dyspnoea and presented to the hospital. The differential diagnosis for the myositis at this time was broad, which included autoimmune, infective, metabolic, paraneoplastic and post-viral inflammatory disease. A thorough infectious workup was negative for viral etiologies including IgM for cytomegalovirus, Epstein-Barr virus, coxsackie virus and human T-lymphotropic virus. The thyroid function was normal. Autoimmune serology was positive for antinuclear antibody (ANA) (1:320, speckled pattern), and very low titre of anti-Smith antibody, which were deemed to be secondary to an acute infectious process.10 She had negative antiphospholipid antibodies and no symptoms of systemic lupus erythematosus.

Anti-Jo-1, anti-signal recognition particle (SRP) and anti-3-hydroxy-3-methylglutaryl–coenzyme A
muscle integrity that leads to the direct release of intracellular muscle components, including myoglobin, creatine kinase, and in severe cases can cause electrolyte imbalances and acute renal failure. Infective myositis presenting as localised muscle group weakness has been associated with viruses such as coxackievirus, parainfluenza, adenovirus, echovirus, Epstein-Barr virus, varicella-zoster virus, cytomegalovirus, herpes simplex and HIV.

As per the literature review, there have been a few cases of rhabdomyolysis related to SARS-CoV-2 but all were reported as acute and concurrent with pneumonia within the first 2 weeks of infection onset. However, this case report is unique with its subacute course and no temporality with the lung involvement when the patient presented with myositis.

NAM is a rare subgroup of autoimmune inflammatory myositis. The aetiology is usually idiopathic, but it has also been associated with statin use, triggered by post-viral autoimmune antibodies and sometimes has manifested as paraneoplastic presentation. It is characterised clinically based on the subacute onset of severe generalised muscle weakness and very high levels of creatine kinase and is histologically differentiated from another inflammatory myositis by the absence or minimal inflammation. Anti-Jo-1, anti-SRP and anti-HMGCR autoantibodies are associated with triggering NAM.

In this case, the patient had SARS-CoV-2 IgG, a month later after the initial COVID-19 infection, she presented with rhabdomyolysis and the symptoms gradually progressed to myositis. All the possible causes that could trigger myositis like acute viral infections, electrolyte imbalances, endocrinopathies and statin were evaluated and ruled out. Autoimmune serology was positive for ANA (1:320, speckled pattern) and very low titre anti-Smith antibody, which were deemed to be secondary to an acute infectious process. The scattered necrotic myofibres with relatively minimal inflammatory cell infiltrates are suggestive of necrotizing autoimmune myopathy. The absence of anti-Jo-1, HMGCR and SRP antibodies made NAM less likely to be entirely an idiopathic autoimmune phenomenon. Henceforth, after a thorough workup, and detailed review of the sequence of the symptoms, COVID-19 IgG-related myositis was the final diagnosis of exclusion.

The pathophysiology of the viral-associated myositis is not well understood. The complement system activated from the deposition of virus–antibody complexes can result in collateral muscle damage, and the circulating viral toxins can also cause direct muscle injury. The T-cell or macrophage-mediated injury was also shown on muscle biopsy in some cases of viral myositis. Interestingly, direct viral muscle invasion is not well established as viral particles are rarely found in a muscle biopsy in cases of acute viral myositis. The ACE 2 receptors, the entry site of SARS-CoV-2, are present on skeletal muscles.

Learning points
- This is the first case reported of COVID-19 immunoglobulin G (IgG)-related autoimmune myositis, confirmed by muscle biopsy and MRI, which improved with the initiation of corticosteroids.
- COVID-19 can present with atypical musculoskeletal manifestations and autoimmunity such as myositis.
- Our case imposes awareness on musculoskeletal autoimmune processes triggered by COVID-19 which requires clinical suspicion for early diagnosis and initiation of treatment.
which necessitate further investigation to identify SARS-CoV-2 as the first virus that can potentially cause direct muscle injury.22

A timely diagnosis of viral antibody-mediated NAM is critical as it can improve outcomes. In the early presentations, the symptoms improved with high-dose corticosteroids and supportive physical therapy.25 The steroids should gradually be tapered over the due course of time. In case there is a relapse of symptoms, then steroid-sparing disease-modifying anti-rheumatic drugs (DMARD) therapy would be considered in the future.26 In conclusion, we present a rare case of inflammatory necrotizing myositis associated with SARS-CoV-2 IgG, timely diagnosis and treatment with high-dose steroids improved the outcome of the patient.

Contributors MV and SK identified the case and wrote the manuscript. BA supervised and managed the case.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID id
Bibi Ayesha http://orcid.org/0000-0003-0410-677X

REFERENCES
1 WjG, ZY N, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382.
2 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395:497–506.
3 Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020;382:2372–4.
4 Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683.
5 Beydon M, Chevalier K, Al Tabaa O, et al. Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis 2020. doi:10.1136/annrheumdis-2020-217573. (Epub ahead of print: 23 Apr 2020).
6 Suwanwongse K, Shabarek N. Rhabdomyolysis as a presentation of 2019 novel coronavirus disease. Cureus 2020;12:e7561.
7 Jin M, Tong Q. Rhabdomyolysis as potential late complication associated with COVID-19. Emerg Infect Dis 2020;26:1618–20.
8 Khan NAJ, Khalid S, Ullah S, et al. Necrotizing autoimmune myopathy: a rare variant of idiopathic inflammatory myopathies. J Invest Med High Impact Case Rep 2017;5:232470961770903.
9 Fadila MF, Wool KJ. Rhabdomyolysis secondary to influenza A infection: a case report and review of the literature. N Am J Med Sci 2015;7:122–4.
10 Ali Y. Rheumatologic tests: a primer for family physicians. Am Fam Physician 2018;98:164–7.
11 Hu J-J, Kao C-L, Lee P-I, et al. Clinical features of influenza A and B in children and association with myositis. J Microbiol Immunol Infect 2004;37:95–8.
12 Torres PA, Helmstetter JA, Kaye AM, et al. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J 2015;15:58–69.
13 Nance JR, Mammen AL. Diagnostic evaluation of rhabdomyolysis. Muscle Nerve 2015;51:793–810.
14 Chen L-I, Hsu C-W, Tian Y-C, et al. Rhabdomyolysis associated with acute renal failure in patients with severe acute respiratory syndrome. Int J Clin Pract 2005;59:1162–6.
15 Husain R, Corcueria-Solano I, Dayan E, et al. Rhabdomyolysis as a manifestation of a severe case of COVID-19: a case report. Radiol Case Rep 2020;15:1633–7.
16 Mukhejee A, Ghosh R, Aftab G. Rhabdomyolysis in a patient with coronavirus disease 2019. Cureus 2020;12:e8956.
17 Boru Uysal B, İkotun H, Yavuzer S, et al. Case report: a COVID-19 patient presenting with mild rhabdomyolysis. Am J Trop Med Hig 2020;103:847–50.
18 Zhang Q, Shan KS, Minnaya A, et al. A rare presentation of coronavirus disease 2019 (COVID-19) induced viral myositis with subsequent rhabdomyolysis. Cureus 2020;12:e8074.
19 Chan KH, Farouji I, Abu Hanoud A, et al. Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19). Am J Emerg Med 2020;38:1548.e1–1548.e3.
20 Dalakas MC. Myositis: are autoantibodies pathogenic in necrotizing myopathy? Nat Rev Rheumatol 2018;14:251–2.
21 Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015;373:1734–47.
22 Dalakas MC. Guillain-Barré syndrome: the first documented COVID-19-triggered autoimmune neuropathic disease: more to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm 2020;7.
23 Adler BL, Christopher-Stine L. Triggers of inflammatory myopathy: insights into pathogenesis. Discov Med 2018;25:75–83.
24 Ilić I, Naib A, Dalakas M. Immunocytochemical and virological characteristics of HIV-associated inflammatory myopathies: similarities with seronegative polymyositis. Ann Neurol 1991;29:474–81.
25 Mastaglia FL, Zilko P. Inflammatory myopathies: how to treat the difficult cases. J Clin Neurosci 2003;10:99–101.
26 Cordeiro AC, Isenberg DA. Treatment of inflammatory myopathies. Postgrad Med J 2006;82:417–24.